Approximately 55% of patients with neuromyelitis optica spectrum disorder show cognitive impairment as evaluated using the Rao Brief Repeatable Neuropsychological Battery. Using well validated ocular motor and conventional nueropsychological assssments, this study aims to determine whether cognitive changes are consistent across the spectrum or whether they are differentially affected in patients who have myelin oligodendrocyte glycoprotein (MOG) antibodies, aquaporin-4 (AQP4) antibodies, or seronegativity for both antibodies.
neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein (MOG) antibodies, aquaporin-4 (AQP4) antibodies, cognitive dysfunction
Central Clinical School » Medicine - Alfred
Masters by research
Top-up scholarship funding available